Jeffrey Nau, Oyster Point Pharma CEO
June 29, 2022 10:43 AM EDTUpdated 11:21 AM
People
Pharma

Feel­ing the heat of the bear mar­ket, eye dis­ease biotech to im­ple­ment 'ex­pense stream­lin­ing' plan and lay off 50

Paul Schloesser

Associate Editor

The com­pa­ny be­hind an FDA-ap­proved in­hal­able form of smok­ing ces­sa­tion aid Chan­tix for dry eye dis­ease is falling in line with quite a few oth­er …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

A service from the Financial Times